MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from debt
$15,000K
Proceeds from issuance of
common stock, net of...
$11,688K
Proceeds from exercise of
stock options
$1,109K
Proceeds from issuance of
common stock under...
$585K
Net cash provided by
(used in) financing...
$13,382K
Canceled cashflow
$15,000K
Net decrease in
cash, cash...
-$61,119K
Canceled cashflow
$13,382K
Share-based compensation
expense
$25,408K
Prepaid expenses and
other current assets
-$5,004K
Right-of-use assets
-$3,696K
Depreciation and
amortization
$3,025K
Impairment of right-of-use
assets
$1,897K
Foreign currency
transaction loss
-$382K
Payments on debt
obligations
$15,000K
Net cash used in
operating activities
-$74,271K
Canceled cashflow
$39,412K
Net cash used in
investing activities
-$230K
Revenue
$82,031K
Other
-$10,477K
Net loss
-$65,783K
Deferred revenue
-$23,872K
Canceled cashflow
$92,508K
Accrued liabilities
-$15,265K
Lease liabilities
-$4,214K
Accounts payable
-$2,959K
Accounts receivable
$1,590K
Acquisition of property and
equipment
$230K
Total research and
development
$112,212K
General and
administrative
$46,079K
Back
Back
Cash Flow
source: myfinsight.com
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)